emmanuelle Charafe-Jauffret

List of Publications by Citations

99 papers	12,457 citations	49 h-index	111 g-index
124 ext. papers	13,923 ext. citations	8 avg, IF	5.34 L-index

#	Paper	IF	Citations
99	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, **2007**, 1, 555-67	18	3079
98	Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Research*, **2009**, 69, 1302-13	10.1	938
97	Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem Cell Reports*, **2014**, 2, 78-91	8	656
96	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *Journal of Clinical Investigation*, **2010**, 120, 485-97	15.9	577
95	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clinical Cancer Research*, **2010**, 16, 45-55	12.9	570
94	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biology*, **2009**, 7, e1000121	9.7	414
93	BRCA1 regulates human mammary stem/progenitor cell fate. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1680-5	11.5	365
92	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. *Oncogene*, **2004**, 23, 1377-91	9.2	265
91	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. *Nature Chemistry*, **2017**, 9, 1025-1033	17.6	254
90	Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. *Cancer Research*, **2006**, 66, 4636-44	10.1	235
89	Integrated profiling of basal and luminal breast cancers. *Cancer Research*, **2007**, 67, 11565-75	10.1	232
88	Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. *Cancer Research*, **2005**, 65, 2170-8	10.1	186
87	Comprehensive profiling of 8p11-12 amplification in breast cancer. *Molecular Cancer Research*, **2005**, 3, 655-67	6.6	178
86	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. *Journal of Pathology*, **2005**, 207, 260-8	9.4	172
85	Retinoid signaling regulates breast cancer stem cell differentiation. *Cell Cycle*, **2009**, 8, 3297-302	4.7	168
84	WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. *Oncogene*, **2001**, 20, 5810-7	9.2	159
83	Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. *Cancer Research*, **2004**, 64, 8558-65	10.1	155

82	Immunophenotypic analysis of inflammatory breast cancers: identification of an ?nflammatory signature?. *Journal of Pathology*, **2004**, 202, 265-73	9.4	150
81	Cancer stem cells in breast: current opinion and future challenges. *Pathobiology*, **2008**, 75, 75-84	3.6	142
80	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. *Cancer Research*, **2005**, 65, 767-79	10.1	141
79	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. *PLoS Genetics*, **2012**, 8, e1002751	6	136
78	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. *Lancet Oncology, The*, **2012**, 13, 375-84	21.7	134
77	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. *American Journal of Pathology*, **2002**, 161, 1223-33	5.8	133
76	Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. *Human Pathology*, **2007**, 38, 830-41	3.7	131
75	Genome profiling of ERBB2-amplified breast cancers. *BMC Cancer*, **2010**, 10, 539	4.8	114
74	Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. *Oncogene*, **1999**, 18, 1903-10	9.2	113
73	The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. *Clinical Cancer Research*, **2013**, 19, 6520-31	12.9	112
72	Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in culture. *Gut*, **2017**, 66, 1802-1810	19.2	111
71	Prognosis and gene expression profiling of 20q13-amplified breast cancers. *Clinical Cancer Research* , **2006**, 12, 4533-44	12.9	104
70	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. *BMC Cancer*, **2007**, 7, 73	4.8	102
69	Identification and validation of an ERBB2 gene expression signature in breast cancers. *Oncogene*, **2004**, 23, 2564-75	9.2	101
68	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. *BMC Cancer*, **2006**, 6, 245	4.8	100
67	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. *Cancer Research*, **2013**, 73, 7290-300	10.1	98
66	Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. *Stem Cells*, **2012**, 30, 1327-37	5.8	97
65	Breast cancer stem cells: tools and models to rely on. *BMC Cancer*, **2009**, 9, 202	4.8	94

64	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. *EMBO Molecular Medicine*, **2011**, 3, 153-66	12	88
63	Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Research*, **2008**, 68, 767-76	10.1	86
62	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. *Cell Reports*, **2017**, 18, 2256-2268	10.6	81
61	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nature Medicine*, **2017**, 23, 568-578	50.5	78
60	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. *Breast Cancer Research*, **2009**, 11, R23	8.3	65
59	High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. *International Journal of Cancer*, **2012**, 130, 96-104	7.5	63
58	Moesin expression is a marker of basal breast carcinomas. *International Journal of Cancer*, **2007**, 121, 1779-85	7.5	63
57	Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. *Molecular and Cellular Proteomics*, **2008**, 7, 1420-33	7.6	62
56	Comparative multi-methodological measurement of ERBB2 status in breast cancer. *Journal of Pathology*, **2004**, 202, 286-98	9.4	58
55	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. *Oncogene*, **2002**, 21, 5619-30	9.2	56
54	Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. *Nature Communications*, **2016**, 7, 10318	17.4	55
53	Comparative genomic analysis of primary tumors and metastases in breast cancer. *Oncotarget*, **2016**, 7, 27208-19	3.3	53
52	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. *PLoS ONE*, **2011**, 6, e16950	3.7	50
51	Chromosome arm 8p and cancer: a fragile hypothesis. *Lancet Oncology, The*, **2003**, 4, 639-42	21.7	49
50	Defining the molecular biology of inflammatory breast cancer. *Seminars in Oncology*, **2008**, 35, 41-50	5.5	47
49	How different are luminal A and basal breast cancers?. *International Journal of Cancer*, **2009**, 124, 1338-48	7.5	46
48	CD44 regulates epigenetic plasticity by mediating iron endocytosis. *Nature Chemistry*, **2020**, 12, 929-938	17.6	45
47	Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clinical Cancer Research*, **2015**, 21, 1298-304	12.9	43

46	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. *PLoS ONE*, **2014**, 9, e81843	3.7	42
45	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 600-11	21.7	35
44	Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. *PLoS ONE*, **2014**, 9, e104302	3.7	35
43	Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopy. *International Journal of Experimental Pathology*, **2003**, 84, 75-81	2.8	32
42	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. *Cancer Research*, **2015**, 75, 3373-83	10.1	29
41	Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. *Genes Chromosomes and Cancer*, **2002**, 35, 204-18	5	29
40	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. *BMC Cancer*, **2008**, 8, 28	4.8	28
39	8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PLoS ONE*, **2012**, 7, e37943	3.7	27
38	ETV6 gene rearrangements in invasive breast carcinoma. *Genes Chromosomes and Cancer*, **2005**, 44, 103-8	5	25
37	Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. *Stem Cells*, **2014**, 32, 3031-6	5.8	24
36	Absence of ESR1 amplification in a series of breast cancers. *International Journal of Cancer*, **2008**, 123, 2970-2	7.5	23
35	MARCKS protein overexpression in inflammatory breast cancer. *Oncotarget*, **2017**, 8, 6246-6257	3.3	21
34	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. *Breast Cancer Research*, **2011**, 13, R109	8.3	18
33	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. *International Journal of Cancer*, **2003**, 107, 854-62	7.5	16
32	Basal and luminal breast cancers: basic or luminous? (review). *International Journal of Oncology*, **2004**, 25, 249-58	1	16
31	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. *Breast*, **2007**, 16, 352-8	3.6	15
30	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. *Oncotarget*, **2018**, 9, 33762-33777	3.3	13
29	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO Molecular Medicine*, **2019**, 11, e9930	12	12

28	Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. *International Journal of Cancer*, **2009**, 124, 896-904	7.5	11
27	Targeting breast cancer stem cells: fishing season open!. *Breast Cancer Research*, **2010**, 12, 312	8.3	9
26	CD95/Fas and metastatic disease: What does not kill you makes you stronger. *Seminars in Cancer Biology*, **2020**, 60, 121-131	12.7	9
25	How to best classify breast cancer: conventional and novel classifications (review). *International Journal of Oncology*, **2005**, 27, 1307-13	1	9
24	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. *Oncotarget*, **2016**, 7, 79428-79441	3.3	8
23	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. *Genome Medicine*, **2021**, 13, 87	14.4	8
22	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/ECatenin Signaling. *Stem Cell Reports*, **2018**, 11, 1040-1050	8	8
21	PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. *Nature Chemical Biology*, **2019**, 15, 358-366	11.7	6
20	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. *Npj Breast Cancer*, **2021**, 7, 41	7.8	6
19	Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. *Advanced Science*, **2021**, 8, 2003049	13.6	6
18	Breast cancer stem cells programs: enter the (non)-code. *Briefings in Functional Genomics*, **2016**, 15, 186-99	4.9	5
17	A stem cell population at the anorectal junction maintains homeostasis and participates in tissue regeneration. *Nature Communications*, **2021**, 12, 2761	17.4	5
16	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 468, 473-81	5.1	4
15	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. *European Journal of Cancer*, **2016**, 57, 118-26	7.5	4
14	Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. *Proteomics*, **2019**, 19, e1800454	4.8	4
13	Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. *Journal of Cancer*, **2016**, 7, 2077-2084	4.5	4
12	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. *Anti-Cancer Drugs*, **2009**, 20, 946-52	2.4	3
11	How to best classify breast cancer: Conventional and novel classifications (Review) **2005**, 27, 1307		3

10	Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells **2002**, 21, 989		3
9	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. *Breast*, **2016**, 27, 8-14	3.6	3
8	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. *Journal of Clinical Medicine*, **2019**, 8,	5.1	2
7	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. *BMC Cancer*, **2015**, 15, 697	4.8	2
6	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. *Journal of Pathology*, **2012**, 227, 267-9	9.4	1
5	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. *Cell Death and Disease*, **2022**, 13, 96	9.8	1
4	CD95/Fas suppresses NF-B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism.. *IScience*, **2021**, 24, 103538	6.1	0
3	Flick the cancer stem cellsPswitch to turn cancer off. *Molecular and Cellular Oncology*, **2017**, 4, e1319896	1.2	
2	Corr□ation imagerie-anatomopathologie en biopsie mammaire : utilit□de la classification europ□nne illustr□ en cas cliniques. *Imagerie De La Femme*, **2015**, 25, 22-31	0.1	
1	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. *Cancers*, **2022**, 14, 2404	6.6	